SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of Earliest Event Reported): June 2, 2016
BIOSPECIFICS TECHNOLOGIES CORP.
(Exact name of registrant as specified in its charter)
|(State or Other Jurisdiction||(Commission File Number)||(I.R.S. Employer|
|Of Incorporation)||Identification No.)|
35 Wilbur Street
Lynbrook, NY 11563
(Address of Principal Executive Office) (Zip Code)
(Registrants telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Throughout this Current Report on Form 8-K, the terms we, us, our and Company refer to BioSpecifics Technologies Corp.
ITEM 5.07. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
The 2016 annual meeting of stockholders of the Company (the 2016 Annual Meeting) was held on June 2, 2016. At the 2016 Annual Meeting, the holders of 6,366,586 shares of the Companys common stock were represented in person or by proxy, thereby constituting a quorum.
Set forth below are the final voting results for each of the matters submitted to a vote of the stockholders of the Company at the 2016 Annual Meeting.
Proposal 1. The stockholders of the Company elected George Gould, Dr. Jyrki Mattila and Michael Schamroth to the Board of Directors, each to serve until the 2019 annual meeting of stockholders or until such person resigns, is removed, or otherwise leaves office. The votes were cast as follows:
|Dr. Jyrki Mattila||4,566,193||109,781|
Proposal 2. The stockholders of the Company approved the ratification of the appointment of EisnerAmper LLP as the Companys independent registered public accounting firm for the fiscal year ending December 31, 2016. The votes were cast as follows:
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|Date: June 3, 2016||BIOSPECIFICS TECHNOLOGIES CORP.|
|/s/Thomas L. Wegman|
|Thomas L. Wegman|